Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct;4(5):220-8.
doi: 10.1177/2042098613498091.

Preparing for safety issues following drug approval: pre-approval risk management considerations

Gretchen S Dieck  1 , Robert G Sharrar  2
Affiliations
Review

Preparing for safety issues following drug approval: pre-approval risk management considerations

Gretchen S Dieck et al. Ther Adv Drug Saf. 2013 Oct.

Abstract

Risk management plans and risk minimization plans as well as postapproval commitment studies are based on risks identified pre-approval that need to be further characterized or minimized in the postmarketing environment. Although the implementation of these activities are conducted in the postapproval arena, the design of the plans and studies as well as the development of effective postapproval tools and mitigation strategies should be carried out pre-approval. The pre-approval period also provides the opportunity to fully understand the treatment population that is included in the clinical trial program and to determine how the target population for the drug after approval may differ from the clinical trial patient population. When regulators or sponsors have expressed concerns about safety issues identified during clinical development, the result may be a postapproval commitment in the form of a registry or an observational safety study or, in the US, a Risk Evaluation and Mitigation Strategy (REMS) as a condition of approval. Specific examples are given for risk mitigation activities that can be conducted pre-approval.

Keywords: postapproval; pre-approval; risk management; risk mitigation; safety.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr Dieck was employed by Pfizer, Inc. from 1986 to 2010. Dr Sharrar was employed by Merck & Co., Inc. from 1991 to 2008.

References

    1. Committee for Medicinal Products for Human Use (CHMP) (2005) Guideline on Risk Management Systems for Medicinal Products for Human Use. Available at: http://web.invima.gov.co/portal/documents/BVSalud/IVC/anexo5emeagrmsmp.pdf (accessed 22 May 2012).
    1. Committee for Medicinal Products for Human Use (CHMP) (2008) Volume 9A of The Rules Governing Medicinal Products in the European Union: Guidelines on Pharmacovigilance for Medicinal Products for Human Use. Available at: http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf (accessed 23 May 2012).
    1. Curkendall S., Mo J., Glasser D., Stang M., Jones J. (2005) Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 65: 715–720 - PubMed
    1. Dieck G., Berger S., Kracov D., Manion D., Tanner A. (2009) Constant vigilance: the role of pharmaceutical companies in medicine safety. Drug Inform J 43: 603–616
    1. European Medicines Agency (2012) Guideline on Good Pharmacovigilance Practices (GVP). Annex I – Definitions. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_li... (accessed 6 June 2013).

LinkOut - more resources